Renal Cancer News

Avastin® and Reduced Doses of Interferon Effective and Tolerable in Advanced Kidney Cancer (08/13/2008)
The addition of the targeted agent Avastin® (bevacizumab) to reduced doses of the immune-stimulating agent interferon appears to improve progression-free survival among patients with advanced kidney cancer while reducing side effects caused by full doses of interferon. These results were recently published in the Annals of Oncology.

Sutent® Provides Superior Quality of Life Compared with Interferon in Kidney Cancer (08/12/2008)
The targeted agent Sutent® (sunitinib) provides superior quality of life compared with interferon alfa for patients with advanced renal cell carcinoma (kidney cancer). These results were recently published in the Journal of Clinical Oncology.

Everolimus Improves Progression-Free Survival in Kidney Cancer (07/28/2008)
The investigative agent everolimus (RAD001) significantly prolongs progression-free survival among patients with advanced kidney cancer who have progressed following prior therapies. These results were recently published in an early on-line version of The Lancet.

Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Kidney Cancer (06/04/2008)
According to updated results from a Phase III clinical trial, initial treatment of metastatic kidney cancer with Sutent® (sunitinib) results in significantly better response rates and progression-free survival than treatment with interferon alfa. These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).

Urologic and Colorectal Cancer Rates Linked in New Study (05/22/2008)
Individuals who have been diagnosed with urologic cancers have an increased risk of developing colorectal cancer, and vice versa, according to data recently published in the Archives of Internal Medicine. These results may provide potential changes in screening guidelines.

More...

General

Avastin® and Reduced Doses of Interferon Effective and Tolerable in Advanced Kidney Cancer (08/13/2008)
The addition of the targeted agent Avastin® (bevacizumab) to reduced doses of the immune-stimulating agent interferon appears to improve progression-free survival among patients with advanced kidney cancer while reducing side effects caused by full doses of interferon. These results were recently published in the Annals of Oncology.

Sutent® Provides Superior Quality of Life Compared with Interferon in Kidney Cancer (08/12/2008)
The targeted agent Sutent® (sunitinib) provides superior quality of life compared with interferon alfa for patients with advanced renal cell carcinoma (kidney cancer). These results were recently published in the Journal of Clinical Oncology.

Everolimus Improves Progression-Free Survival in Kidney Cancer (07/28/2008)
The investigative agent everolimus (RAD001) significantly prolongs progression-free survival among patients with advanced kidney cancer who have progressed following prior therapies. These results were recently published in an early on-line version of The Lancet.

Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Kidney Cancer (06/04/2008)
According to updated results from a Phase III clinical trial, initial treatment of metastatic kidney cancer with Sutent® (sunitinib) results in significantly better response rates and progression-free survival than treatment with interferon alfa. These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).

Urologic and Colorectal Cancer Rates Linked in New Study (05/22/2008)
Individuals who have been diagnosed with urologic cancers have an increased risk of developing colorectal cancer, and vice versa, according to data recently published in the Archives of Internal Medicine. These results may provide potential changes in screening guidelines.

More...